Oliver Lagore Vanvalin Investment Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Oliver Lagore Vanvalin Investment Group’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3	Closed	–	–	790
2022 Q3	$0	Hold	3	–	–	﹤0.01%	776
2022 Q2	$0	Buy	+3	New	+$284	﹤0.01%	743

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Oliver Lagore Vanvalin Investment Group's HZNP Position: Q4 2022 in Review

Oliver Lagore Vanvalin Investment Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 3 shares.

Oliver Lagore Vanvalin Investment Group first reported a position in HZNP in Q2 2022 and held it in 2 quarters. The position peaked at $0 in Q3 2022. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

Oliver Lagore Vanvalin Investment Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Oliver Lagore Vanvalin Investment Group sold 3 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022.
Oliver Lagore Vanvalin Investment Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022 and held it in 2 quarters.
Oliver Lagore Vanvalin Investment Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $0 in Q3 2022.
615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Oliver Lagore Vanvalin Investment Group's 13F filing for Q4 2022, filed 2 Mar 2023.